Oskira-3: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To a Tumor Necrosis Factor-alpha Antagonist
Author(s):
Genovese, M.; Heijde, D. van der; Keystone, E.; Spindler, A.; Benhamou, C.L.; Kavanaugh, A.; Fudman, E.; Lampl, K.; O'Brien, C.; Duffield, E.; Poiley, J.; Weinblatt, M.
Published
2013
Publication type
Article / Letter to editor
Date issued
2013-10-31
Language
English
Is part of
Arthritis and Rheumatism (2013), Vol. 65, p. S199-S200
